- Home
- JHX vs QGEN Comparison
JHX vs QGEN Comparison
Compare JHX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JHX | QGEN |
|---|---|---|
| Founded | 1888 | 1986 |
| Country | Ireland | Netherlands |
| Employees | N/A | 5700 |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | JHX | QGEN |
|---|---|---|
| Price | $19.94 | $47.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $28.60 | ★ $50.68 |
| AVG Volume (30 Days) | ★ 6.6M | 1.2M |
| Earning Date | 11-17-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | 0.40 | ★ 1.84 |
| Revenue | ★ $4,116,899,999.00 | $2,070,781,000.00 |
| Revenue This Year | $24.54 | $7.12 |
| Revenue Next Year | $15.32 | $6.13 |
| P/E Ratio | $59.44 | ★ $25.56 |
| Revenue Growth | 4.60 | ★ 5.32 |
| 52 Week Low | $16.46 | $37.63 |
| 52 Week High | $29.83 | $51.88 |
Technical Indicators
Market Signals| Indicator | JHX | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 55.46 |
| Support Level | $19.14 | $46.39 |
| Resistance Level | $19.90 | $48.13 |
| Average True Range (ATR) | 0.57 | 0.67 |
| MACD | 0.31 | 0.18 |
| Stochastic Oscillator | 97.74 | 68.53 |
Price Performance
Historical ComparisonAbout JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Following the Azek acquisition in 2025, it also produces wooden composite decking materials, siding trims, and accessories for outdoor areas including stair and deck railing. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).